| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (NCT03997968) | Cyteir Therapeutics, Inc. | 2019-10-09 |
| NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma (NCT04136756) | Nektar Therapeutics | 2019-10-07 |
| A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma (NCT04082936) | IGM Biosciences, Inc. | 2019-09-30 |
| An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma (NCT03779113) | Hutchmed | 2019-09-26 |
| Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation (NCT03755414) | Washington University School of Medicine | 2019-09-04 |
| Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies (NCT04068597) | CellCentric Ltd. | 2019-08-09 |
| A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) (NCT04035434) | CRISPR Therapeutics AG | 2019-07-22 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT04045028) | Genentech, Inc. | 2019-07-22 |
| Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) (NCT03768505) | MEI Pharma, Inc. | 2019-06-25 |
| Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) (NCT03904134) | Center for International Blood and Marrow Transplant Research | 2019-06-14 |
| A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies (NCT03913949) | Ascentage Pharma Group Inc. | 2019-06-03 |
| CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma (NCT04237428) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2019-05-31 |
| Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx (NCT03923504) | Virginia Commonwealth University | 2019-05-10 |
| Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (NCT03570892) | Novartis Pharmaceuticals | 2019-05-09 |
| Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation (NCT03925935) | Angiocrine Bioscience | 2019-05-07 |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003) (NCT03645395) | Molecular Templates, Inc. | 2019-04-08 |
| Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma (NCT03713580) | Case Comprehensive Cancer Center | 2019-03-12 |
| Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (NCT03666000) | Imugene Limited | 2019-03-11 |
| VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies (NCT03885947) | Alla Keyzner | 2019-02-21 |
| Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (NCT03610724) | Novartis Pharmaceuticals | 2019-02-15 |
| Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning (NCT03852407) | University of Liege | 2019-02-04 |
| Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy (NCT03790891) | Timmune Biotech Inc. | 2019-01-05 |
| Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma (NCT03602131) | Sichuan University | 2019-01-01 |
| Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant (NCT03438344) | City of Hope Medical Center | 2018-12-01 |
| Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) (NCT03711578) | Rhizen Pharmaceuticals SA | 2018-11-25 |
| Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment (NCT03706625) | Assistance Publique - Hôpitaux de Paris | 2018-11-20 |
| Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation (NCT03734601) | Stanford University | 2018-11-05 |
| Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma (NCT03688451) | Tahir Latif | 2018-10-29 |
| Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL (NCT03806179) | Nordic Nanovector | 2018-10-04 |
| Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies (NCT03671590) | TG Therapeutics, Inc. | 2018-09-10 |
| CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant (NCT03560752) | City of Hope Medical Center | 2018-08-20 |
| DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (NCT03620578) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2018-08-01 |
| Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors (NCT03615105) | Memorial Sloan Kettering Cancer Center | 2018-07-25 |
| A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS (NCT03573310) | Janssen Research & Development, LLC | 2018-07-13 |
| AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma (NCT03434769) | Benjamin Tomlinson | 2018-07-09 |
| Patient Preference for Pegfilgrastim (Neulasta®) Application Forms (NCT03619993) | iOMEDICO AG | 2018-06-25 |
| Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients (NCT03528421) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2018-05-22 |
| Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 (NCT02890758) | Brenda Cooper, MD | 2018-05-22 |
| CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (NCT03454451) | Corvus Pharmaceuticals, Inc. | 2018-04-25 |
| Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL (NCT03379051) | TG Therapeutics, Inc. | 2018-03-27 |
| A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL (NCT03467373) | Hoffmann-La Roche | 2018-03-13 |
| Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma (NCT03185325) | Assiut University | 2018-03-10 |
| Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (NCT03424603) | Sutro Biopharma, Inc. | 2018-02-22 |
| Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product (NCT03436771) | Juno Therapeutics, a Subsidiary of Celgene | 2018-02-19 |
| Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy (NCT03595813) | Institut Paoli-Calmettes | 2018-01-29 |
| Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (NCT03355859) | Zhao Weili | 2018-01-05 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) (NCT02657447) | Nordic Nanovector | 2017-12-19 |
| Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies (NCT03422679) | Cellestia Biotech AG | 2017-12-05 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (NCT03169790) | ImmunityBio, Inc. | 2017-12-01 |
| 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation (NCT03133221) | University of Maryland, Baltimore | 2017-10-23 |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL (NCT03019666) | Masonic Cancer Center, University of Minnesota | 2017-10-18 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma (NCT03096782) | M.D. Anderson Cancer Center | 2017-10-13 |
| Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma (NCT03311126) | University of Wisconsin, Madison | 2017-09-29 |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (NCT03212404) | Checkpoint Therapeutics, Inc. | 2017-09-20 |
| Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen (NCT03595800) | Institut Paoli-Calmettes | 2017-09-19 |
| Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCT03192397) | Roswell Park Cancer Institute | 2017-08-09 |
| Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials (NCT03207256) | TG Therapeutics, Inc. | 2017-08-09 |
| Cyclophosphamide and Alemtuzumab In Lymphoma (NCT03132584) | Dana-Farber Cancer Institute | 2017-07-30 |
| Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies (NCT03056339) | M.D. Anderson Cancer Center | 2017-06-21 |
| A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL) (NCT03571308) | University Hospital Southampton NHS Foundation Trust | 2017-06-02 |
| CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (NCT02917083) | Baylor College of Medicine | 2017-05-08 |
| Identification of Occupational Exposures in Acute Hematologic Malignancy (NCT03316209) | Centre Hospitalier Intercommunal Creteil | 2017-04-27 |
| Auto Stem Cell Transplant for Lymphoma Patients (NCT03125642) | Masonic Cancer Center, University of Minnesota | 2017-04-20 |
| Familial Investigations of Childhood Cancer Predisposition (NCT03050268) | St. Jude Children's Research Hospital | 2017-04-06 |
| Bergamo Lymphoid Cancer Registry (NCT03131531) | A.O. Ospedale Papa Giovanni XXIII | 2017-03-23 |
| Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide (NCT03065790) | Abramson Cancer Center at Penn Medicine | 2017-02-06 |
| Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide (NCT03088709) | Loyola University | 2017-01-18 |
| Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery (NCT02955043) | University of Wisconsin, Madison | 2016-12-22 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NCT01962636) | Masonic Cancer Center, University of Minnesota | 2016-12-01 |
| Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant (NCT02115126) | David Rizzieri, MD | 2016-12-01 |
| Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NCT02953509) | Gilead Sciences | 2016-11-21 |
| Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure (NCT03323541) | University Hospital, Brest | 2016-11-03 |
| Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery (NCT02767388) | University of Nebraska | 2016-09-01 |
| A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma (NCT02811679) | Massachusetts General Hospital | 2016-08-01 |
| Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) (NCT02624388) | University of Virginia | 2016-08-01 |
| A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor (NCT02640833) | AbbVie | 2016-07-01 |
| Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients (NCT03127020) | PIQUR Therapeutics AG | 2016-06-01 |
| Auto/Allo Tandem Transplant for Relapsed B-NHL (NCT03205657) | New York Medical College | 2016-06-01 |
| Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects (NCT02519270) | Spectrum Pharmaceuticals, Inc | 2016-05-01 |
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer (NCT02595866) | National Cancer Institute (NCI) | 2016-04-04 |
| DS-3201b in Participants With Lymphomas (NCT02732275) | Daiichi Sankyo Co., Ltd. | 2016-03-31 |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies (NCT02639559) | Washington University School of Medicine | 2016-03-31 |
| Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) (NCT02669017) | ADC Therapeutics S.A. | 2016-03-01 |
| Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors (NCT02508038) | University of Wisconsin, Madison | 2016-02-12 |
| Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) (NCT02568683) | Gilead Sciences | 2016-02-11 |
| A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma (NCT02702141) | Seagen Inc. | 2016-02-01 |
| Use of EBUS TBNA for Cell Culture as an Aid to Diagnose Lung Cancer and Lymphoma (NCT02710565) | Mid and South Essex NHS Foundation Trust | 2016-02-01 |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) (NCT02631044) | Juno Therapeutics, a Subsidiary of Celgene | 2016-01-06 |
| Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (NCT02506933) | City of Hope Medical Center | 2015-12-21 |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies (NCT02529813) | M.D. Anderson Cancer Center | 2015-12-16 |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (NCT02593123) | Virginia Commonwealth University | 2015-11-04 |
| Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency (NCT02553447) | University of Nebraska | 2015-10-19 |
| Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A (NCT02406092) | Hoffmann-La Roche | 2015-10-13 |
| Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma (NCT02432235) | ADC Therapeutics S.A. | 2015-10-05 |
| Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies (NCT02543879) | Forma Therapeutics, Inc. | 2015-09-01 |
| Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies (NCT02507479) | Sheba Medical Center | 2015-09-01 |
| Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (NCT02393157) | New York Medical College | 2015-08-21 |
| The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (NCT02736357) | Mayo Clinic | 2015-07-01 |